References
- Groop L. C., Luzi L., Melander A., Groop P. H., Ratheiser K., Simonson D. C., DeFronzo R. A. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 1987; 36: 1320–8
- Groop L., Groop P. H., Stenman S., Saloranta C., Totterman K. J., Fyhrquist F., Melander A. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care 1987; 10: 671–8
- Wåhlin-Boll E., Aimer L-O, Melander A. Bioavailability, pharmacokinetics and effects of glipizide in Type 2 diabetics. Clin Pharmacokinet 1982; 7: 363–72
- Heding L. G. Determination of total serum insulin (IRI) in insulin treated diabetic patients. Diabe-tologia 1972; 8: 260–6
- Heding L. G. Radioimmunological determination of human C-peptide in serum. Diabetologia 1975; 11: 541–8
- Wåhlin-Boll E., Melander A. High-performance liquid chromatographic determination of glipizide and some other sulphonylurea drugs in serum. J Chromatogr 1979; 164: 541–6
- Aimér L-O, Johansson E., Melander A., Wahlin-Boll E. Influence of sulphonylureas on the secretion, disposal and effect of insulin. Eur J Clin Pharmacol 1982; 22: 27–32
- Scheen A. J., Levfebre P. J., Luyckx A. S. Glipizide increases plasma insulin but not C-peptide level after a standardized breakfast in Type 2 diabetic patients. Eur J Clin Pharmacol 1984; 26: 471–4
- Simpson R. G., Bendetti A., Grodsky G. M., Karam J. H., Forsham P. H. Early phase of insulin release. Diabetes 1968; 18: 684–92
- DeFronzo R. A. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667–87
- Perley M., Kipnis D. M. Plasma insulin responses to glucose and tolbutamide of normal weight and obese diabetic and non-diabetic subjects. Diabetes 1966; 15: 867–74
- Savage P. J., Dippe S. R., Bennet P. H., Gorden R., Roth J., Rushforth N. B., Miller M. Hyperinsulinaemia. Insulin response to oral carbohydrate over a wide spectrum of glucose tolerance. Diabetes 1974; 24: 362–8
- Eriksson J., Franssila-Kallunki A., Ekstrand A., Sal-oranta C., Widen E., Schalin C., Groop L. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989; 321: 337–43
- Bitzén P-O, Melander A., Scherstén B., Svensson M. Efficacy of dietary regulation in primary health care patients with hyperglycaemia detected by screening. Diabetic Medicine, 188(5)640–7
- Henry R. R., Wallace P., Olefsky M. Effect of weight loss on mechanisms of hyperglycemia in obese non-insulin dependent diabetes mellitus. Diabetes 1986; 35: 990–8
- Judzewitsch R. G., Pfeiffer M. A., Best J. D., Beard J. C., Halter J. B., Porte D. Chronic chlorpropamide therapy of non-insulin dependent diabetes mellitus augments basal and stimulated insulin secretion by increasing islet sensitivity to glucose. J Clin Endocrinol Metab 1982; 55: 321–8
- Hecht A., Gershberg H., Hulse M. Effect of chlorpropamide treatment on insulin secretion in diabetics: its relationship to the hypoglucemic effect. Metabolism 1973; 22: 723–33
- Bitzén P. O., Melander A., Scherstén B., Svensson M., Wåhlin-Boll E. Long-term effects of glipizide on insulin secretion and blood glucose control in patients with non-insulin-dependent diabetes mellitus. Eur J Clin Pharmacol 1992; 42: 77–83